XML 27 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2021   283,130,000      
Beginning balance at Mar. 31, 2021 $ 1,113,601 $ 283 $ 1,653,328 $ (513,799) $ (26,211)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive loss (478)       (478)
Restricted stock units vested (in shares)   1,305,000      
Restricted stock units vested 0 $ 1 (1)    
Restricted stock awards forfeited (in shares)   (20,000)      
Issuance of common stock related to employee stock purchase plan (in shares)   372,000      
Issuance of common stock related to employee stock purchase plan 13,913 $ 1 13,912    
Exercise of stock options (in shares)   1,266,000      
Exercise of stock options 25,489 $ 1 25,488    
Share-based compensation 99,536   99,536    
Equity repurchases (66)   (66)    
Net income 52,451     52,451  
Ending balance (in shares) at Mar. 31, 2022   286,053,000      
Ending balance at Mar. 31, 2022 1,304,446 $ 286 1,792,197 (461,348) (26,689)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive loss (5,140)       (5,140)
Restricted stock units vested (in shares)   2,139,000      
Restricted stock units vested 0 $ 2 (2)    
Restricted stock awards forfeited (in shares)   (15,000)      
Issuance of common stock related to employee stock purchase plan (in shares)   553,000      
Issuance of common stock related to employee stock purchase plan 17,806   17,806    
Exercise of stock options (in shares)   1,681,000      
Exercise of stock options 32,939 $ 2 32,937    
Share-based compensation 146,874   146,874    
Equity repurchases (15)   (15)    
Net income $ 107,959     107,959  
Ending balance (in shares) at Mar. 31, 2023 290,411,108 290,411,000      
Ending balance at Mar. 31, 2023 $ 1,604,869 $ 290 1,989,797 (353,389) (31,829)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive loss (3,570)       (3,570)
Restricted stock units vested (in shares)   4,376,000      
Restricted stock units vested 0 $ 4 (4)    
Restricted stock awards granted (in shares)   142,000      
Issuance of common stock related to employee stock purchase plan (in shares)   534,000      
Issuance of common stock related to employee stock purchase plan $ 19,472 $ 1 19,471    
Exercise of stock options (in shares) 1,500,000 1,500,000      
Exercise of stock options $ 31,191 $ 2 31,189    
Share-based compensation 208,896   208,896    
Net income $ 154,632     154,632  
Ending balance (in shares) at Mar. 31, 2024 296,962,547 296,963,000      
Ending balance at Mar. 31, 2024 $ 2,015,490 $ 297 $ 2,249,349 $ (198,757) $ (35,399)